Press Releases

Gilead Sciences to Release Fourth Quarter and Year End 2005 Financial Results on Monday, January 30, 2006; Conference Call and Webcast to Follow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2006--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its fourth quarter and year end 2005 financial results will be released on Monday, January 30, 2005, at 4:00 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead will webcast a conference call live on the company's internet site. The call will be led by John Martin, PhD, President and Chief Executive Officer, John Milligan, PhD, Executive Vice President and Chief Financial Officer, and Kevin Young, Executive Vice President, Commercial Operations. Gilead management will discuss the company's fourth quarter and year end 2005 results, provide an overview of the company, and an outlook and financial guidance for 2006.

To access the webcast via the internet, log on to Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-866-761-0749 (U.S.) or 1-617-614-2707 (international) and dial the participant passcode 30987097 to access the call. Telephone replay is available approximately two hours after the call through 4:00 p.m. Eastern Time, February 1, 2006. To access, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 13311464. The webcast will be archived on for one year.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715
SOURCE: Gilead Sciences, Inc.